The first individual has been administered TH104 in a Phase 1 clinical trial, focusing on the drug's safety, tolerability, and absolute bioavailability.

Sangamo Therapeutics has reported positive interim results from its Phase 1/2 STAAR clinical trial for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease.

ProLynx Inc. initiated a Phase I/II clinical study involving PLX038, a PEGylated form of SN-38, for treating primary central nervous system (CNS) tumors with MYC or MYCN gene amplifications.

ProfoundBio has launched the Phase 1/2 clinical trial for PRO1107, marking a significant step in their mission to enhance patient outcomes.

Rani Therapeutics Holdings, Inc. reported encouraging topline results from its Phase 1 clinical trial of RT-111, a RaniPill® capsule containing an ustekinumab biosimilar (CT-P43).

This study is focused on evaluating the safety and effectiveness of TAC101-CLDN18.2, an advanced cell therapy that utilizes genetically modified autologous T cells.

In the early 20th century, Alois Alzheimer identified neuroinflammation as a factor in the disease now named after him, noting the presence of microglia cells in his initial sketches.

TILT Biotherapeutics' one abstract highlights encouraging safety and efficacy findings of TILT-123 in patients with ovarian cancer.

May 30th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

selectION, Inc. declared the commencement of a Phase 1b study involving its leading candidate si-544 in adult individuals suffering from psoriasis vulgaris or psoriatic arthritis.

Novel Bispecific Antibody REGN7075 (EGFRxCD28) Shows Anti-Tumor Effects with Libtayo® (cemiplimab); Findings to be Presented at ASCO.

I-Mab Releases Promising Phase 1 Results for PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024.